Welcome to our dedicated page for Eikon Therapeutics SEC filings (Ticker: EIKN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Eikon Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Eikon Therapeutics's regulatory disclosures and financial reporting.
Eikon Therapeutics reported higher operating spending and losses for 2025 but ended the year with a much stronger cash position following its IPO. Research and development expenses rose to $250.3 million in 2025, up 22%, reflecting expanded clinical trial activity and its move into a new Millbrae headquarters.
General and administrative expenses increased to $88.6 million, mainly due to a $21.3 million asset impairment and higher compensation costs. Net loss attributable to common stockholders widened to $333.6 million, or $115.29 per share. Cash, cash equivalents, and marketable securities were $336.0 million at year-end, and a February 2026 upsized IPO raised an additional $381.2 million in gross proceeds, which the company expects will fund operations into the second half of 2027.
Eikon Therapeutics is a late-stage clinical biopharmaceutical company focused on oncology, advancing multiple candidates including EIK1001, EIK1003, EIK1004, EIK1005 and EIK1006. The company reported a 2025 net loss of $324.2 million, driven mainly by research and development spending of $250.3 million and general and administrative costs of $88.6 million.
Cash, cash equivalents and marketable securities totaled $336.0 million at year-end, and a February 2026 IPO added about $349.0 million of net proceeds, which management expects to fund operations into the second half of 2027. Eikon highlights a material weakness in internal control over financial reporting and notes a prior restatement of 2025 interim financials, as well as substantial future funding needs typical for a clinical-stage biotech with an accumulated deficit of $920.5 million.
Eikon Therapeutics, Inc. reported that Chief Operating Officer Michael A. Klobuchar received a grant of stock options for 87,157 shares at an exercise price of $0.00 per share. The award vests in equal monthly installments over 48 months, subject to his continued service.
Huffines Robert Luther reported acquisition or exercise transactions in this Form 4 filing.
Eikon Therapeutics, Inc. reported that director Robert Luther Huffines received a grant of stock options covering 25,873 shares of the company’s stock. These options were awarded as a form of compensation and will vest in equal monthly installments over 48 months, as long as he continues in service during that period.
FRAZIER KENNETH C reported acquisition or exercise transactions in this Form 4 filing.
Eikon Therapeutics director Kenneth C. Frazier reported a new stock option grant covering 25,873 shares of Eikon Therapeutics common stock on March 2, 2026. The option vests in equal monthly installments over 48 months, conditioned on his continued service with the company.
PERLMUTTER ROGER M reported acquisition or exercise transactions in this Form 4 filing.
Eikon Therapeutics director and officer Roger M. Perlmutter received a grant of stock options covering 268,176 shares of the company’s stock. The options were awarded at no cash cost on the grant date. According to the vesting terms, 1/48 of the underlying shares vest monthly over 48 months, contingent on his continued service.
Eikon Therapeutics, Inc. reported that executive Benjamin Bruno Thorner received a grant of stock options covering 67,044 shares of the company’s stock. The options have an exercise price of $0.00 per share and represent a new award rather than an open-market purchase.
According to the vesting terms, one forty-eighth of the option shares will vest on each monthly anniversary of the vesting start date over 48 months, as long as Thorner continues to provide service to the company. This structure ties the award to multi-year retention and ongoing employment.
Eikon Therapeutics Chief Medical Officer Roy D. Baynes reported an option grant giving him rights to acquire 134,088 shares of company stock at an exercise price of $0.00 per share. The option vests in equal monthly installments over 48 months, conditioned on his continued service.
Eikon Therapeutics Chief Financial Officer receives new stock option grant. CFO Alfred Lloyd Bowie Jr. was granted stock options for 67,044 shares of Eikon Therapeutics, Inc. common stock on March 2, 2026, at an exercise price of $0.00 per share, recorded as a grant or award acquisition.
The option vests over four years: 1/48th of the underlying shares vest on each monthly anniversary of the vesting start date for 48 months, provided he continues in service through each vesting date. Following this grant, he directly holds options covering 67,044 shares.
Eikon Therapeutics ownership update: Abu Dhabi Investment Authority reports beneficial ownership of 2,816,714 shares of common stock, representing 5.2% of the class. The filing cites a shares outstanding base of 53,984,337 after giving effect to the offering described in the prospectus filed pursuant to Rule 424(b)(4) on February 5, 2026.
Platinum Falcon B 2018 RSC Limited is reported as the direct owner of 1,147,138 shares (shown as 2.1% of the class); Platinum Falcon is a wholly owned subsidiary of Abu Dhabi Investment Authority and certain voting/dispositive powers are shared between them.